Company logo

OWLT - Owlet, Inc.

NYSE -> Healthcare -> Medical Devices
Lehi, United States
Type: Equity

OWLT price evolution
OWLT
(in millions $) 30 Oct 2024 30 Jul 2024 1 May 2024 31 Jan 2024
Current assets
Cash
Short term investments
Net receivables $17.15 $16.89 $11.6 $13.97
Inventory $10.6 $8.1 $7.74 $6.49
Total current assets $52.28 $42.53 $40.02 $39.94
Long term investments
Property, plant & equipment $0.22 $0.41 $0.86 $1.31
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $56.13 $45.9 $43.83 $44.12
Current liabilities
Accounts payable $11.52 $17.51 $16.06 $13.68
Deferred revenue
Short long term debt
Total current liabilities $35.69 $42.15 $39.45 $45.09
Long term debt $4.58
Total noncurrent liabilities
Total debt
Total liabilities $65.52 $66.73 $65.62 $73.8
Shareholders' equity
Retained earnings -$259.14 -$253.53 -$252.38 -$255.66
Other shareholder equity
Total shareholder equity
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 31 Jan 2021
Current assets
Cash $1.29
Short term investments
Net receivables $13.97 $16 $10.5 $10.53
Inventory $6.49 $18.5 $18 $7.91
Total current assets $39.94 $51.3 $135.8 $1.56
Long term investments
Property, plant & equipment $1.31 $3.4 $1.9 $1.72
Goodwill & intangible assets
Total noncurrent assets
Total investments
Total assets $44.12 $58.1 $140 $231.61
Current liabilities
Accounts payable $13.68 $30.4 $27.8 $16.38
Deferred revenue
Short long term debt
Total current liabilities $45.09 $66.6 $69.1 $0.32
Long term debt $8 $10.18
Total noncurrent liabilities
Total debt
Total liabilities $73.8 $68.7 $84.8 $31.9
Shareholders' equity
Retained earnings -$255.66 -$222.76 -$143.42 -$8.25
Other shareholder equity -$10.6 $55.2
Total shareholder equity
(in millions $) 30 Oct 2024 30 Jul 2024 1 May 2024 31 Jan 2024
Revenue
Total revenue $22.12 $35.45 $14.75 $21
Cost of revenue
Gross Profit $11.55 $16.8 $6.55 $9.87
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $16.37 $24.79 $12.29 $12.95
Operating income
Income from continuing operations
EBIT
Income tax expense $0.02 $0.01
Interest expense -$0.11 -$0.14 -$0.16 -$0.19
Net income
Net income -$6.76 -$0.78 $1.95 -$8.22
Income (for common shares)
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 31 Jan 2021
Revenue
Total revenue $54.01 $69.2 $75.8
Cost of revenue
Gross Profit $22.59 $23.31 $35
Operating activities
Research & development
Selling, general & administrative
Total operating expenses $51.22 $107.93 $90.8 $0.48
Operating income
Income from continuing operations
EBIT
Income tax expense $0.01 $0.03
Interest expense -$3.19 -$1.1 -$27.9 -$7.19
Net income
Net income -$37.49 -$79.34 -$71.7 -$8.25
Income (for common shares)
(in millions $) 30 Oct 2024 30 Jul 2024 1 May 2024 31 Jan 2024
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.72 -$0.12 -$0.05 -$0.06
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $20.58 $5.6 $5.23 $28.91
Effect of exchange rate
Change in cash and equivalents $5.33 -$1.19 $1.84 $5.33
(in millions $) 31 Jan 2024 31 Jan 2023 31 Jan 2022 31 Jan 2021
Net income
Operating activities
Depreciation
Business acquisitions & disposals
Stock-based compensation
Total cash flows from operations
Investing activities
Capital expenditures
Investments
Total cash flows from investing -$0.06 -$1.57 -$2 -$230
Financing activities
Dividends paid
Sale and purchase of stock
Net borrowings
Total cash flows from financing $28.91 -$0.88 $120.6 $231.74
Effect of exchange rate
Change in cash and equivalents $5.33 -$83.83 $78 $1.29
Fundamentals
Market cap $69.89M
Enterprise value N/A
Shares outstanding 15.39M
Revenue $93.33M
EBITDA N/A
EBIT N/A
Net Income -$13.81M
Revenue Q/Q 27.44%
Revenue Y/Y N/A
P/E ratio -5.06
EV/Sales N/A
EV/EBITDA N/A
EV/EBIT N/A
P/S ratio 0.75
P/B ratio N/A
Book/Share N/A
Cash/Share N/A
EPS -$0.90
ROA -29.07%
ROE N/A
Debt/Equity N/A
Net debt/EBITDA N/A
Current ratio 1.46
Quick ratio 1.17